

## Review

## Risk genes in head and neck cancer: A systematic review and meta-analysis of last 5 years



M. Brunotto<sup>a,\*</sup>, A.M. Zarate<sup>a</sup>, A. Bono<sup>b</sup>, J.L. Barra<sup>c</sup>, S. Berra<sup>d</sup>

<sup>a</sup> Departamento de Biología Bucal, Facultad de Odontología, Universidad Nacional de Córdoba, Argentina

<sup>b</sup> Departamento de Patología Bucal, Facultad de Odontología, Universidad Nacional de Córdoba, Argentina

<sup>c</sup> CIQUIBIC, UNC-CONICET, Departamento de Química Biológica, Facultad Ciencias Químicas, Universidad Nacional de Córdoba, Argentina

<sup>d</sup> Instituto de Investigaciones en Ciencias de la Salud (INICSA-CONICET), Universidad Nacional de Córdoba, Argentina

## ARTICLE INFO

## Article history:

Received 17 September 2013

Received in revised form 9 December 2013

Accepted 11 December 2013

Available online 25 December 2013

## Keywords:

Head and neck cancer

Risk polymorphisms

Systematic review

Meta-analysis

## SUMMARY

The aim of this work was to identify risk genes related to the development and progression of squamous cell carcinoma head and neck (SCCHN) and do a meta-analysis of available estimates. Eligible gene/poly-morphism studies were identified by electronic searches. Individual participant data of 8540 patients with HNC and 9844 controls from 19 genetic studies were analyzed, yielding adjusted (tobacco, gender, age and alcohol) odds ratios (OR) and 95% confidence intervals (CIs) comparing cases with controls. A meta-analysis was done on the studies that applied fixed and random models. People have an increase of polymorphism expression related to inflammation (NFKB1-294-ATTG, TNF $\alpha$ 308-A2A2/A2A1, and TNF $\beta$ 252- B2B2/B2B1) or carcinogenic metabolism (GSTM1 null, and CYP1A1 m1/m1), representative of malignancy development. Furthermore, the increased expression of genes associated with the stabilization and repair of the cellular (OGG1-Asp267Asn, Ser279Gly Ile253Phe, 1578A > T, 1582C > T Ala399-Glu (1542C > A) 1582insG 1543\_1544delCT), and genes associated with the regulation of proliferation, apoptosis or tumor survival (miRNA499-CT/CC, CRYABC802G-CG/GG) are considered as risk factors. In this scheme, only the polymorphisms of ADH7A92G-GG and DEC1606-T/C genes are protective against malignancy transformation. The TP53, GSTM1 and CYP1A1 genes have been evaluated in more than one study and analyzed for homogeneity in each genotype. The meta-analysis showed no significant association between different allelic variants of Arg72Pro rs1042522 and SCCHN risk.

In a model of tumorigenesis, an increased risk of SCCHN is associated with DNA repair and DNA stabilization genes. In addition, the polymorphisms involved in inflammation and carcinogenic metabolism processes represent an increased risk of SCCHN.

© 2013 Elsevier Ltd. All rights reserved.

## Introduction

Head and Neck Carcinoma (HNC), of which the majority are squamous cell carcinomas of the head and neck (SCCHN), is the sixth most prevalent cancers in mankind and, presents high morbidity and low rates of survival [1]. It is known that the apoptotic and proliferation genes are involved in cancer development and these could be useful as a biomarker of this pathology. Systematic reviews and meta-analysis allow stronger and more generalized conclusions for identifying some models of risk markers. These models may help in screening, early diagnosis and/or therapy in the clinic [2–5].

In recent decades, there has been increased interest in genetic predisposition studies in complex disease. This has led to the production of an enormous number of epidemiologic papers about the relationship between genetic polymorphism and disease. However, the magnitude of association between specific polymorphism and disease is still not established. The identification of a predictive model of risk polymorphisms could help in early diagnosis, and in understanding disease recurrence and/or progression in the subset of patients.

Vineis et al. [6] summarized five proposed models in the history of cancer research as follows: *-Mutational*: carcinogenic compounds such as tobacco produce mutations in the genes related to cell cycle regulation [7]; *Genome Instability*: based on the tumor suppressor genes hypothesis and DNA repair (*mismatch repair*), and microsatellite instability [8]; *Non-Genotoxic*: based on modulators of cancer risk (epigenetic events) such as diet, obesity, and hormones [9]; *Darwinian*: based on Darwin's theory and the work of researchers such as Greaves, 2007 [10]. This model considers a

\* Corresponding author. Address: Cátedra Biología Celular, Facultad de Odontología, Universidad Nacional de Córdoba, Haya de La Torre s/n, Pabellón Argentina, Ciudad Universitaria, CP 5000 Córdoba, Argentina. Tel.: + 54 351 43333032/76x214.

E-mail address: [brunottomabel@gmail.com](mailto:brunottomabel@gmail.com) (M. Brunotto).

clonally selection of cells that acquire advantages over others rather than mutations, but places the emphasis on the role of the macro- and micro-environment; *Tissue Organization*: focuses on the local micro-environment around the precancerous cells. There are two subtypes: focused on the micro-environment (focal proliferative lesions precede cancer) or morphostasis theory (morphostatic fields maintain the normal behavior of the cell and its tissue micro-architecture) [11].

The aim of this work was to identify risk genes related to the development and progression of squamous cell carcinoma head and neck (SCCHN) and do a meta-analysis of available estimates.

## Methods

### Search strategy and selection criteria

This study was made according to the PRISMA reporting items for systematic reviews and meta-analysis guidelines. We conducted a systematic review and meta-analysis of case-control studies from the MEDLINE, Scopus, Cochrane, and CancerLit databases between January 2007 and January 2013. Language is not restricted. The search strategy included the following keywords (variably combined): “oral cancer”, “oral cancer polymorphism”, “oncogene”, “tumor suppressor gene”, “squamous cell carcinoma”, “head and neck cancer”.

### Data extraction

Data was collected of adult patients of both genders, with diagnosis of head and neck carcinoma according to the criteria of ICD-10C00-C14 WHO or another specific source, in whom genetic polymorphisms were identified. Original published papers that did not report genotyping by PCR (polymerase chain reaction), or studies of patients with systemic diseases or with syndromes, pregnancy or with indication of long-term medication were excluded.

Abstracts and titles of all the identified papers obtained by the electronic search were evaluated. All studies which met the inclusion criteria (presence/absence of mutation and/or polymorphism by PCR, Odd Ratios (OR) adjusted for alcohol and tobacco, 95% confidence intervals (CIs) were assessed in order to establish their validity and subsequent data extraction.

### Evaluation of quality of studies

The case-control studies guidelines of the Scottish Intercollegiate Guidelines Network and MOOSE are followed. Two members of the team (AB, AMZ) evaluated complete articles independently and double-blinded, to establish their quality. Disagreements were resolved by reiteration, discussion and consensus with the participation of a third member (JLB). The papers were encoded and delivered independently to each reviewer. A search was made of combined electronic databases, and the bibliographies of all selected papers were searched to identify grey literature.

### Statistical analysis

Since the included polymorphisms are diallelic SNPs, odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were used to assess the strength of association between each gene variant and HNC risk, based on meta-analysis of molecular association studies [12].

Meta-analysis was performed using the random-effects (DerSimonian Laird) model, based on whether the homogeneity characteristics of the studies allowed us to assume that the effect size

(HCN risk) varies between studies (studies represent a population of true effects), and the fixed effects by the Mantel Haenszel method (assumes that all studies belong to a common population, and that the effect size is not significantly different between studies.) To this end, heterogeneity was formally investigated by the  $Q$ -test and the  $I^2$  statistic  $I^2 = \frac{Q-df}{Q} \times 100\%$  [13]. The *meta* package of R software 2.15.3 (March 2013) was used.

### Role of the funding source

The funders had no role in study design, data collection, analysis or interpretation of data, preparation of the report, or the decision to publish. All members of the analysis and writing committee had access to the raw data and are responsible for the final submission for publication.

## Results

Nineteen original reports were retrieved from 2285 potential reports that addressed the issue of DNA gene/polymorphisms and risk of SCCHN. Twelve of the studies were of unpaired case-control design, 6 studies were matched case-control, and 1 nested case-control (Table 1). All studies were adjusted for tobacco and alcohol. Clinical trials, chromosomal alterations or *in vitro* cell culture studies were not included. ORs and 95% CIs were estimated between case-control and presence/absence of SCCHN. Other aspects were also studied that are not included in this paper because they are not homogenous.

A hundred and eight genotypes of 40 polymorphism/genes (Table 2) related to proliferation, apoptosis, carcinogenic metabolism, inflammatory and progression pathways were analyzed. The total number was 8540 cases and 9844 controls (Table 2). The number of males was higher than females. The average age range was between 50 and 60 years old, but the age ranged from 20 to 80, and was similar in both cases and controls. In two studies only males were enrolled [14,15].

The following genes/polymorphisms were seen to have significant association with increased risk of SCCHN: miRNA499 [15], TNF $\alpha$  [16], TNF $\beta$  [16], NFKB1 [17], NFKBIA [17], CRYAB (Alpha B-Crystalline) [18], OGG1 [19], CYP1B1 [20], and GSTM1 [21,22]. In contrast, the ADH7A92G [23], and DEC1 [24] polymorphisms are associated with a diminished risk of SCCHN. TP53, GSTM1, and CYP1A1 were described in four, three, and two studies respectively, which were considered for meta-analysis.

The suppressor tumor gene TP53, Arg72Pro, rs1042522 (CC, GG, CG) polymorphism was evaluated in four studies for CC/GG genotypes, and in three studies for the CG genotype [24–27]. No study reported a significant association between this polymorphism and SCCHN risk. The studies reporting the genotype data were homogenous for the CC genotype ( $I^2 = 40.1\%$ ,  $Q$ -test = 5.01,  $p$ -value = 0.1714), GG genotype ( $I^2 = 0\%$ ,  $Q$ -test = 2.69,  $p$ -value = 0.447), and CG genotype ( $I^2 = 0\%$ ,  $Q$ -test = 0.66,  $p$ -value = 0.7171). For each genotype pooled, the OR observed was: CC genotype 1.14, CIs 95% [0.9195; 1.4208],  $p$ -value = 0.2285; GG genotype 0.97, CIs 95% [0.8837; 1.0707],  $p$ -value = 0.5723; GC genotype 0.91, CIs 95% [0.8191; 1.0058],  $p$ -value = 0.0645. The meta-analysis showed no significant association between different allelic variants of Arg72-Pro rs1042522 and SCCHN risk (Fig. 1).

The GSTM1 polymorphism was evaluated in three studies [21,22,28]. No study reported a significant association between this polymorphism and SCCHN risk. For the positive genotype ( $I^2 = 87.4\%$ ,  $Q$ -test = 15.87,  $p$ -value = 0.0004) and null genotype ( $I^2 = 84\%$ ,  $Q$ -test = 12.53,  $p$ -value = 0.0019), heterogeneity was significant. Accordingly, there was no indication to meta-analyze the data.

**Table 1**  
 Characteristics of Studies. SCCHN: squamous cell carcinoma head and neck; OSCC: oral squamous cell carcinoma; CC: case-control study; AF: absolute frequency; RF: relative frequency. M: male; F: female.

Gene/polymorphism	Authors	Origin	Design	Diagnosis	Cases (place)	Controls (place)	Gender AF (RF)	Age (years) Average ± SD
CYP1B1	Pradhan et al. [20]	India	CC matched	OSCC	51 Bangalore Institute of Oncology, Bangalore, India	51 R.L. Jalappa Hospital Research Center, India	Both	
CYP1A1 GTSM1	Cordero et al. [21]	Chile	CC	OSCC	48 National Institute of Cancer	124 Santiago, Chile	Cases. 16 F 32 M Controls: 57 F 67 M	Cases. 62.3 ± 10 Control 50.4 ± 14
ADH1B R48H (rs1229984: G > A)	Wei et al. [23]	USA	CC	SCCHN	1110 The University of Texas M.D. Anderson Cancer Center	1129 The University of Texas M.D. Anderson Cancer Center visitantes	Cases. 273 (24.6) F	Cases. 57.2 (±11.1)
ADH7A92G (rs1573496: C > G)							837 (75.4) M Controls 270 (23.9) F 859 (76.1) M	Controls 56.8 (±11.0)
IGFBP7 702G > C, 418G > A,	Huang et al. [62]	USA	CC	SCCHN	1065 The University of Texas M.D. Anderson Cancer Center	1112 The University of Texas M.D. Anderson Cancer Center visitantes	Cases. 262 (24.6) F	Cases. 57.2 ± 11.2
GSTM1 CYP1A1	Cha et al. [22]	Korea	CC	OSCC	72 Department Oral and maxilofacial Surgery Yonsei University College of Dentistry	221 School or college of dentistry	Cases 26 F	Cases 62.5 ± 12.3
p53exon4 (Arg72Pro), intron 3 – 6 p73 G4C14 a- A4T14	Galli et al. [27]	Italy	CC	SCCHN	283 cases Hospital "A. Gemelli" the Università Cattolica Sacro Cuore	295 Hospital controls	46 M Controls 108 F 113 M Cases	Controls 35.4 ± 17.5
DEC1 21628 G > A 2606 T > C 2249T > C 2122 G > A c.179 C > T TP53 codon 72 (Arg72Pro)	Huang et al. [24]	USA	CC matched	SCCHN	1111 (100.0) The University of Texas. D. Anderson Cancer Center.	1130 (100.0)	Cases 177 (60.0) M 274 (24.7) F	Controls 63.5 ± 13.1 Cases 57.1 ± 11.1
TAX1BP1 TT:wild homozygote; TA: heterozygote; AA: polymorphic homozygote	Ruiz et al. [64]	Brazil	CC	SCCHN	191	200	860 (76.1) M Cases 29 (15.2) F	Controls 56.8 ± 11.0 270 (23.9) F
							162 (84.8) M Controls	Controls 47.55 ± 15.69

TNF- $\alpha$ -308G/A TNF- $\beta$ 252G/A	Yapjajakis et al. [16]	Greece Germany	CC matched	OSCC	160	153	47 (23.5) F 153 (76.5) M	Cases 128 M Controls 115 M	Cases 58.5 $\pm$ /10.1 Controls 56.1 $\pm$ /12.1
Alpha B-Crystallin CRYAB A-1215G (rs2228387), C-802G (rs14133)	Bau et al. [18]	China Taiwan	CC nested	OSCC	496 China Medical University Hospital, Taichung, Taiwan, Republic of China	992	27 (5.4) F	469 (94.6) M	Controls 63.8 $\pm$ 8.4
intron2 (rs2070894)							469 (94.6) M	Controls	
MDM2 309 GT + GG,	Yu et al. [26]	USA	CC matched	SCCHN	1083 The University of Texas M.D. Anderson Cancer Center	1090	78 (7.9) F 914 (92.1) M	Cases 269 (24.8) F	Cases 57.1
2164 AA, p53 codon 72 CC							814 (75.2) M Controls 258 (23.7) F	Controls 56.7	
NFKB1 294ATGG1/ATGG2,	Lin et al. [17]	Taiwan	CC	OSCC	462 Chung Shan Medical University Hospital Taichung and Changhua Christian Hospital and Show Chwan Memorial	520 Chung Shan Medical University Hospital Taichung and Changhua Christian Hospital and Show Chwan Memorial	832 (76.3) M Cases 18 F	Controls 54.46 $\pm$ 11.4	
294 ATGG2/ATGG2, NFKBIA							444 M Controls 94 F 426 M	Controls 52.46 $\pm$ 14.7	
2826 T (CT + TT) 2881 G (AG + GG) GSTM1, GSTT1 CYP1A1	Amtha et al. [28]	Indonesia	CC	OSCC	81 Hospital Jakarta	162 Hospital Jakarta	Cases 31 (38.3) F 50 (61.7) M Controls 62 (38.3) F 100 (61.7) M	Cases 47.4 $\pm$ 12.4	
RECK gene rs10814325,	Chung et al. [14]	Taiwan	CC	SCCHN	341 Chung Shan Medical University Hospital Taichung Changhua Christian Hospital y Show Chwan Memorial	415 Show Chwan Memorial Hospital, Changhua Christian Hospital Chung Shan Medical University Hospital	341 M Controls 415 M		
rs16932912, rs11788747 rs10972727 OGG1 (mutations) Asp267Asn, Ser279Gly Ile253Phe, 1578A > T, 1582C > T	Mahjabeenet al. [19]	Pakistan	CC matched	SCCHN	300 National Oncology Radiotherapy Institute (NORI) Pakistan Institute of Medical Sciences (PIMS).	300 National Oncology Radiotherapy Institute (NORI) Pakistan Institute of Medical Sciences (PIMS).			
Ala399Glu (1542C > A) 1582insG 1543_1544delCT L-MYC	Bektas-Kayhan et al. [63]	Turkish	CC matched.	OSCC	80 Estambul University Medical Faculty Department of	60	No consigna	Cases 54.9 $\pm$ 13.21 Controls	

Table 1 (continued)

Gene/polymorphism	Authors	Origin	Design	Diagnosis	Cases (place)	Controls (place)	Gender AF (RF)	Age (years)	Average ± SD
BAX (-248 C.A) BCL2 (-838 C.A)	Chen et al. [25]	USA	CC	SCCHN	Otorhinolaryngology and Department of Radiation Oncology 814 University of Texas M.D. Anderson Cancer Center.	934 University of Texas M.D. Anderson Cancer Center	Cases 194 (23.8) F	50.82 ± 11.11 Cases 57.0 ± 11.0	
TP53 (Arg72Pro)	Galbiatti et al. [65]	Brazil	CC	SCCHN	322 Hospital de Base, a Public Institution, Sao José do Rio Preto, Sao Paulo, Brazil	531	620 (76.2) M Controls 233 (25.0) F 701 (75.0) M Cases 13.3% F	55.9 ± 11.2 Both 52.5 ± 13.7	
CBS 844ins68							86.7% M Controls 27.7% F 72.3% M M 100% Cases/controls		
MicroRNA miRNA146a, miRNA196, miRNA499, miRNA149	Chu et al. [15]	Taiwan	CC	OSCC	470 Chung Shan Medical University Hospital-Taichung Changhua Christian Hospital Show Chwan Memorial Hospital – Changhua	425 From three hospitals			

The CYP1A1 polymorphism was evaluated in two studies [21,28]. No single study reported a significant association between this polymorphism and SCCHN risk. The genotype data were homogenous for wild/wild genotype ( $I^2 = 73.3\%$ ,  $Q$ -test = 3.74,  $p$ -value = 0.0531) and wild/m1 genotype ( $I^2 = 70.3\%$ ,  $Q$ -test = 3.37,  $p$ -value = 0.0665) (Fig. 2). For the m1/m1 genotype ( $I^2 = 86.9\%$ ,  $Q$ -test = 7.64,  $p$ -value = 0.0057) heterogeneity was significant, which prevented meta-analyzing the data.

## Discussion

Despite the great molecular advances made in understanding the mechanism of SCCHN tumorigenesis, there are still numerous points that are unclear or unknown. The evaluation of diagnostic markers such as symptoms and genetic tests helps to increase the sensitivity or specificity of the determination of the presence/absence of malignancy [2,3,29].

Cancer is a complex pathology, and its incidence and survival index are closely related to social, cultural and socio-economic determinants of health.

Most of studies included in this paper are from the United States, but Europe, Asia and South America are also represented. Nonetheless, it is not possible to compare the prevalence of HNC among the countries, because this is influenced by variables such as ethnicity, geographic latitude and individual genetic background which are not included in all the studies [1]. Generally, low-income countries are more exposed to environmental risk factors such as, infections, tobacco, alcohol, unhealthy diet plus, in many situations, little access to health systems and health education [30]. Genes related to pathways of cell cycle regulation (proliferation, apoptosis, differentiation, proliferation, epigenetic) were included in this review and meta-analysis.

The p53, Mdm2, p73, and miRNA proteins are involved in proliferation control and cellular apoptosis. In this review, there was no reported significant association of TP53, Mdm2, and p73 polymorphisms with SCCHN [24–27]. It is known that the p53 suppressor tumor gene has a key role in stress cellular response, to preserve genome stability, and it is universally recognized as a human cancer marker when it is mutated [2,31–34]. Actually, there is a TP53 polymorphism that produces a protein with an amino acid (arginine or proline) located at position72 [35].

Cellular functions of this polymorphism were studied in *in vitro* culture, and it was observed that the protein variant codon72 arginine (R72) has a suppressor function of malignancy and induces an increase in apoptotic activity in relation to the variant 72 proline (P72) [36,37]. Authors such as Sarkar et al. [38] have demonstrated that this polymorphism modulates the hyper-proliferative, apoptotic, and inflammatory phenotypes caused by HPV16 E6 and E7 oncoproteins. They also observed that it modifies the response to chemical carcinogens (e.g. 4NQO), suggesting that variant P72 could increase the risk of some cancers and that there is a tissue-specific difference in the response to environmental carcinogens. Epidemiological studies differ about the association of various cancers with this polymorphism R72P, with some reporting and others denying the association [39,40]. Furthermore the literature on this issue in relation to oral cancer is scarce.

One of the miRNA polymorphisms has been associated with increased SCCHN risk. The miRNA are small portions of RNA, approximately 20–22 nucleotides, which may target a specific messenger RNA and generate feedback of its translation efficiency and stability [41–45]. 25% of all known human miRNAs are significantly deregulated in at least some kind of cancer such as HNC [46].

DEC1-606 polymorphism was related to a decrease of HNC risk. This gene is expressed in the majority of normal human tissues, but has been observed deregulated in some tumors such as breast,

**Table 2**  
Polymorphisms studied.

Author	Country	Diagnosis	Polymorphism	Genotype	OR <sup>a</sup>	CI 95%	Cases	Controls				
Cordero et al. [21]	Chile	OSCC	CYP1A1	wt/wt	1.00 <sup>a</sup>		22	75				
				wt/m1	2.08	1.00–4.29	22	36				
				m1/m1	1.04	0.30–3.56	4	13				
				Positive	1.00 <sup>a</sup>		24	100				
Wei et al. [23]	USA	SCCHN	ADH1B R48H (rs1229984: G > A)	Null	<b>4.16</b>	<b>1.95–8.89</b>	24	24				
				GG	1.00 <sup>a</sup>		1059	1075				
				AG	1.33	0.88–2.02	51	52				
				AA	NA	NA	0	2				
				AG + AA	0.96	0.65–1.42	51	54				
				CC	1.00 <sup>a</sup>		948	902				
				CG	0.79	0.62–1.00	156	206				
				GG	<b>0.32</b>	<b>0.13–0.82</b>	6	21				
				CG + GG	<b>0.74</b>	<b>0.59–0.94</b>	162	227				
				Huang et al. [62]	USA	SCCHN	IGFBP7 418G > A (rs 4075349)	GG	1.00 <sup>a</sup>		395	369
AG	<b>0.82</b>	<b>0.67–0.99</b>	506					571				
AA	0.85	0.65–1.11	164					172				
AG + AA	<b>0.82</b>	<b>0.69–0.99</b>	670					743				
GG	1.00 <sup>a</sup>		794					791				
CG	0.83	0.68–1.02	251					301				
CC	0.91	0.47–1.74	20					20				
CG + CC	0.83	0.68–1.02	271					321				
Positive	1.00 <sup>a</sup>		35					86				
Cha et al. [22]	Korea	OSCC	GSTM1					Null	0.7	0.4–1.3	37	123
				wt/wt	1.00 <sup>a</sup>		20	49				
				wt/m1	0.8	0.4–1.4	30	97				
				m1/m1	<b>3.3</b>	<b>1.4–10</b>	22	17				
Galli et al. [27]	Italy	SCCHN	p53intron 3 (rs1788332)	wt	1.00 <sup>a</sup>		191	209				
				M	1.30	0.81–2.10	92	86				
				Arg Arg	1.00 <sup>a</sup>		175	169				
				Pro	1.07	0.68–1.67	108	126				
				GG	1.00 <sup>a</sup>		194	192				
				C	0.99	0.63–1.58	89	86				
				GG/GC	1.00		187	214				
				AT	1.51	0.94–2.43	96	81				
				GG	1.00 <sup>a</sup>		1008	1021				
				Huang et al. [24]	USA	SCCHN	DEC1–1628 G > C (rs1591420)	CG	1.03	0.75–1.42	89	90
CC	0.33	0.03–3.16	1					4				
CG + CC	1.00	0.73–1.37	90					94				
TT	1.00 <sup>a</sup>		529					537				
CT	0.95	0.79–1.14	492					481				
CC	<b>0.71</b>	<b>0.52–0.99</b>	89					112				
TT + CT	<b>0.73</b>	<b>0.54–0.99</b>	1021					1018				
TT	1.00 <sup>a</sup>		403					429				
CT	1.11	0.92–1.35	522					499				
CC	0.87	0.66–1.44	144					177				
Ruiz et al. [64]	Brazil	SCCHN	TAX1BP1	TT + CT	0.82	0.64–1.05	925	928				
				GG	1.00 <sup>a</sup>		859	882				
				AG	1.10	0.88–1.36	221	222				
				AA	1.46	0.70–3.03	18	11				
				AG + AA	1.12	0.90–1.38	239	236				
				GG	1.00 <sup>a</sup>		576	617				
				CG	0.96	0.79–1.15	398	445				
				CC	1.28	0.89–1.83	80	68				
				TT	1.00 <sup>a</sup>		34	94				
				TA + AA	0.82	0.36–1.87	11	26				
Yapijakis et al. [16]	Greece Germany	OSCC	TNF- $\alpha$ -308G/A	A1/A1	1.00 <sup>a</sup>		36	121				
				A2/A2	<b>17.51</b>	<b>8.6–35.6</b>	75	13				
				A1/A2	<b>8.33</b>	<b>4.04–17.15</b>	49	19				
				B1/B1	1.00 <sup>a</sup>		28	108				
				B2/B2	<b>40.83</b>	<b>13.8–120.8</b>	82	3				
				B1/B2	<b>5.09</b>	<b>2.69–9.64</b>	50	42				
Bau et al. [18]	China Taiwan	OSCC	CRYAB A-1215G (rs2228387)	GG	1.00 <sup>a</sup>		491	981				
				AG	0.91	0.31–2.63	5	11				
				AA	NA	NA	0	0				
				CC	1.00 <sup>a</sup>		301	703				
				CG	<b>1.51</b>	<b>1.18–1.92</b>	158	245				
				GG	<b>1.96</b>	<b>1.24–3.10</b>	37	44				
				Yu et al. [26]	USA	SCCHN	CRYAB intron2 (rs2070894)	CC	1.00 <sup>a</sup>		325	688
								CT	1.18	0.93–1.51	150	268
								TT	1.23	0.71–2.15	21	36
								TT	1.00 <sup>a</sup>		463	488
GT	1.11	0.92–1.34	486					472				
GG	1.08	0.81–1.43	134					136				
Yu et al. [26]	USA	SCCHN	Mdm2 309 (T > G; rs2279744)	GT/GG	1.10	0.92–1.32	620	602				

(continued on next page)

Table 2 (continued)

Author	Country	Diagnosis	Polymorphism	Genotype	OR <sup>a</sup>	CI 95%	Cases	Controls				
Lin et al. [17]	Taiwan	OSCC	Mdm2 A2164G (rs937283)	AA	1.00 <sup>a</sup>		369	355				
				AG	0.98	0.81–1.20	522	529				
				GG	0.83	0.64–1.07	187	205				
				AG/GG	0.95	0.79–1.14	709	734				
				GG	1.00 <sup>a</sup>		593	597				
			TP53 codon 72 (rs 1042522; G > C)	CG	0.95	0.79–1.14	405	428				
				CC	1.30	0.91–1.86	85	65				
				CG + CC	1.00	0.83–1.19	490	493				
				Del/Del	1.00 <sup>a</sup>		100	168				
				Del/Ins	<b>1.8</b>	<b>1.1–2.7</b>	246	271				
			NFKB1–294 ATTG	Ins/Ins	<b>2.2</b>	<b>1.2–4.2</b>	116	81				
				Del/Ins + Ins/Ins	<b>1.8</b>	<b>1.2–2.8</b>	362	352				
				CC	1.00		381	432				
				CT	1.3	0.9–2.2	78	86				
				TT	5.4	0.4–74.1	3	2				
			NFKBIA-519 T	CT + TT	1.4	0.9–2.2	81	88				
				CC	1.00 <sup>a</sup>		351	438				
				CT	1.6	1.0–2.6	101	78				
				TT	3.4	0.6–18.3	10	4				
				CT + TT	<b>1.7</b>	<b>1.2–2.7</b>	111	82				
			NFKBIA-826	AA	1.00 <sup>a</sup>		351	438				
AG	1.6	1.0–2.6		101	78							
GG	3.4	0.6–18.3		10	4							
AG + GG	<b>1.7</b>	<b>1.2–2.7</b>		111	82							
NFKBIA-881	Wt	1.00 <sup>a</sup>			32	72						
	Null	1.19	0.70–2.02	49	90							
	Wt	1.00 <sup>a</sup>		44	95							
	Null	1.19	0.72–2.05	37	67							
	Wt	1.00 <sup>a</sup>		45	77							
Amtha et al. [28]	Indonesia	OSCC	GSTM1	Polymorphism	0.70	0.39–1.25	36	85				
				TT	1.00 <sup>a</sup>		95	120				
				TC	0.80	0.49–1.31	143	189				
			GSTT1	CC	1.13	0.65–1.99	103	106				
				TC + CC	0.89	0.57–1.38	246	295				
				GG	1.00 <sup>a</sup>		155	214				
			CYP1A1	GA	1.27	0.84–1.93	155	169				
				AA	0.97	0.44–2.13	31	32				
				GA + AA	1.21	0.82–1.80	186	201				
			Chung et al. [14]	Taiwan	SCCHN	RECK rs10814325	AA	1.00 <sup>a</sup>		208	237	
							AG	0.79	0.51–1.23	106	153	
							GG	1.10	0.49–2.46	27	25	
						RECK rs16932912	AG + GG	0.82	0.55–1.22	133	178	
							TT	1.00 <sup>a</sup>		208	236	
							TA	0.83	0.54–1.28	111	152	
RECK rs11788747	AA	0.82				0.35–1.92	22	27				
	TA + AA	0.81				0.54–1.21	133	179				
	Mutation	<b>8.79</b>				<b>4.91–15.8</b>	49					
Mahjabeenet al. [19]	Pakistan	SCCHN				OGG1 Asp267Asn	Mutation	<b>8.94</b>	<b>5.09–15.7</b>	53		
							OGG1 Ser279Gly	Mutation	<b>8.00</b>	<b>3.54–18.1</b>	24	
							OGG1 Ile253Phe, 1578A > T, 1582C > T	Mutation	<b>8.83</b>	<b>4.95–15.8</b>	50	
Bektas-Kayhan et al. [63]	Turkish	OSCC	OGG1 Ala399Glu1543_1544delCT	Mutation	<b>9.27</b>	<b>5.48–15.7</b>	62					
				L-MYC	LL		31	22				
				LS		30	27					
Chen et al. [25]	USA	SCCHN	BAX (–248 G > A; rs4645878)	SS			19	11				
				GG	1.00 <sup>a</sup>		627	723				
				AG	0.99	0.78–1.26	170	200				
				AA	2.01	0.91–4.47	17	11				
				AG + AA	1.04	0.82–1.32	187	211				
			BCL2 (–838 C > A; rs2279115)	CC	1.00 <sup>a</sup>		226	257				
				AC	0.97	0.76–1.22	382	446				
				AA	1.03	0.78–1.35	206	231				
			TP53 codon 72 (rs 1042522; G > C)	AC + AA	0.99	0.79–1.23	588	677				
				GG	1.00 <sup>a</sup>		417	484				
				CG	1.02	0.83–1.26	324	383				
				CC	1.21	0.83–1.76	73	67				
Galbiatti et al. [65]	Brazil	SCCHN	CBS 844ins68	CG + CC	1.05	0.86–1.28	397	450				
				NN	1.00 <sup>a</sup>		258	443				
				IN	1.15	0.74–1.79	56	78				
Chu et al. [15]	Taiwan	OSCC	miRNA146a, rs 2910164	II			8	10				
				CC	1.00 <sup>a</sup>		174	175				
				CG	1.18	0.82–1.70	242	196				
			miRNA149, rs 2292832	GG	0.59	0.32–1.08	54	54				
				TT	1.00 <sup>a</sup>		345	315				
				CT	0.76	0.49–1.17	88	84				
CC	1.45	0.75–2.83	37	26								


Table 2 (continued)

Author	Country	Diagnosis	Polymorphism	Genotype	OR*	CI 95%	Cases	Controls
			miRNA196, rs 11614913	TT	1.00 <sup>a</sup>		136	132
				CT	1.14	0.78–1.68	277	206
				CC	0.74	0.42–1.30	87	57
			miRNA499, rs3746444	TT	1.00 <sup>a</sup>		339	356
				CT	<b>1.79</b>	<b>1.16–2.75</b>	119	66
				CC	<b>4.52</b>	<b>1.24–16.48</b>	12	3


\* OR adjusted by habits, age, and gender.

<sup>a</sup> Reference category. NA: not calculated. SCCHN: squamous cell carcinoma head and neck; OSCC: oral squamous cell carcinoma. Bold: OR-CI 95% significant association.

**Genotype CC**



**Genotype GG**



**Genotype CG**




Figure 1. Meta-analysis of TP53 R72P polymorphism.

stomach, colon, lung, liver and adenocarcinoma of pancreatic duct, probably by hypoxia events [47].



The polymorphisms of genes TNF- $\alpha$ , TNF- $\beta$ , NFKB1, and NFKBIA, involved in inflammatory pathways, have been seen to be associated with increased SCCHN risk [16]. For some years it has been known that cancer spreads uncontrollably from transformed cells, which ought to be recognized by the immune system before they become a tumor. Nevertheless, in a high number of cases, the transformed cells evade immune defenses. Authors such as Piva et al. [48] have observed inflammatory infiltrate in epithelial dysplasia with overexpression of NFKB and TNF- $\alpha$ , establishing a connection between the cancer and inflammation.

Nuclear factor  $\kappa$  is a transcription factor which activates in response to signals from T-cell receptors and is necessary for cytokine synthesis. These signals activate the kinase phosphorylation pathway and continue with the insertion of multiple

copies of a small protein named ubiquitin that releases the NF- $\kappa$ B protein. This protein enters the cell nucleus and induces transcription of cytokine and receptor genes such as interleukin 2 (IL-2), tumor necrosis factor (TNF), and bacterial lipoproteins [49]. Some studies have reported the risk of Hodgkin's lymphoma, multiple myeloma, breast cancer, prostate cancer, stomach cancer, colorectal cancer and melanoma, associated with the polymorphic variation of NFKB1 and NFKBIA genes [17]. Only one of the studies included described a mutation related to increasing SCCHN risk. This study was about 8-oxiguanineDNA glycosylase gene (OGG1), which is involved in DNA repair mechanisms [50,51].

The studies of Cordero et al. [21], Amtha et al. [28] and Cha et al. [22] showed an association with SCCHN risk and the presence of CYP1A1, CYP1B1, and GSTM1 polymorphisms, related to carcinogenic metabolism.



**Genotype wt/wt****Genotype wt/m1**

**Figure 2.** Meta-analysis of CYP1A1 polymorphism. Study 1: Cordero et al. [21]; study 2: Amtha et al. [28].

It is widely known that tobacco is a risk factor of SCCHN and is closely related to the intensity and duration of this habit. Cigarettes contain carcinogens such as nitrosamines and polycyclic hydrocarbons. Those components have genotoxic effects and change the molecular profile of persons through the mutations they cause [52]. CYP1B1 belongs to family 1 of cytochrome P450 and has a significant role in the oxidation process of carcinogens such as the components of cigarette smoke [53]. Boyle et al. [54] compared the transcriptome of the oral mucosa and upper airway of smokers versus non-smokers, and observed an overexpression of CYP1A1 and CYP1B1 genes. Pickett et al. [55] also demonstrated a strong increase in CYP1A1 and CYP1B1 gene expression involved in xenobiotic and detoxification functions.

GSTM1 polymorphisms were also included in this study. This gene encodes glutathione S-transferase Mu 1, which is critical to detoxification and the removal of electrophilic carcinogens. Deletions of this gene have been suggested as a risk factor in colorectal, pancreatic and esophageal cancers, among others [56].

The ADH7A92G [23] polymorphism has been described as associated with diminished SCCHN risk. As well as smoking, alcohol consumption is another known cancer risk factor. In oral mucosa, alcohol acts as a solvent and promotes an increased exposure of oral mucosa to carcinogenic agents, enabling their cellular uptake. Acetaldehyde, an alcohol metabolite, may produce DNA adducts which interfere with synthesis and repair of DNA [57]. The evidence of carcinogenic effects of alcohol consumption on oral and pharyngeal cancers has been widely documented since 1988 [7]. The risk of developing cancer increases according to the amounts of alcohol consumed. A meta-analysis of 7954 cases estimated the relative risk as 1.75 (1.70–1.82) in people who consumed 25 g/day and 2.85 (2.70–3.04) for a consumption of 50 g/day [58]. The AA genotype of the ADH1B R48H gene encodes an enzyme that is about 40 times more active than the enzyme encoded by AG and GG genotypes. The AA genotype is more frequent in Asia but is rare in Europe [57,59].

CRYAB (Alpha B-Crystalline) C-802G polymorphism has been described as having an associated increase of HNC risk. This gene is related to an increase of tumor survival because it promotes angiogenesis and inhibits apoptosis. Lost or diminished CRYAB expression is recognized as a prognostic marker of such cancers as prostate and HNC [60,61]. Research by Su et al. [61] showed that allele G of CRYAB C-802G is correlated to breast cancer risk, and could be useful as a clinical marker for its early detection.

The model proposed in this work shows the genetic composition of individuals that could be at risk or protected against

malignancy transformation. All genotypes are heterozygous or homozygous for polymorphic variant, not wild type. In our model, people have an increase of polymorphism expression related to inflammation (NFKB1-294-ATTG, TNF $\alpha$ 308-A2A2/A2A1, and TNF $\beta$ 252-B2B2/B2B1) or carcinogenic metabolism (GSTM1 null, and CYP1A1 m1/m1), representative of malignancy development. Furthermore, the increased expression of genes associated with the stabilization and repair of the cellular genome (OGG1-Asp267Asn, Ser279Gly Ile253Phe, 1578A > T, 1582C > T Ala399Glu (1542C > A) 1582insG 1543\_1544delCT), and genes associated with the regulation of proliferation, apoptosis or tumor survival (miRNA499-CT/CC, CRYABC802G-CG/GG) are considered as risk factors. In this scheme, only the polymorphisms of ADH7A92G-GG and DEC1606-T/C genes are protective against malignancy transformation. Compared with the models described by Vineis et al. [6], the model proposed in this paper could fit models 1, 2, and 3 because it considers such epigenetic events as inflammation, mutational compounds such as tobacco and alcohol, and genomic stability and the cell cycle regulation process.

### Contributors

MB conceived and coordinated the project, made all the analyses, and wrote the report. All authors contributed individual patient data from trials and commented on the initial surrogate-end point protocol and on drafts of the report.

### Conflict of interest statement

None declared.

### Acknowledgment

The authors received financial support from the Secretaria de Ciencia y Técnica of the Universidad Nacional de Córdoba (Res SECYT, UNC – No. 214/10).

### References

- [1] Petersen PE. Oral cancer prevention and control – the approach of the World Health Organization. *Oral Oncol* 2009;45:454–60.
- [2] Zarate AM, Brezzo MM, Secchi DG, Barra JL, Brunotto M. Malignancy risk models for oral lesions. *Med Oral Patol Oral Cir Bucal* 2013. <http://dx.doi.org/10.4317/medoral.18374>.

- [3] Brunotto M, Zarate AM. Predictive models for complex diseases. *Rev Fac Cien Med Univ Nac Cordoba. Rev* 2012;69(1):33–41.
- [4] Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. *J Dent Res* 2008;87(1):14–32.
- [5] Campo-Trapero J, Cano-Sánchez J, Palacios-Sánchez B, Sánchez-Gutiérrez JJ, González-Moles MA, Bascones-Martínez A. Update on molecular pathology in oral cancer and precancer. *Review. Anticancer Res* 2008;28:1197–206.
- [6] Vineis P, Schatzkin A, Potter JD. Models of carcinogenesis: an overview. *Carcinogenesis* 2010;31(10):1703–9.
- [7] IARC. IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: some miscellaneous pharmaceutical substances. *IARC Monogr Eval Carcinog Risk Chem Man* 1977;13:1–255.
- [8] Knudson A. Retinoblastoma: teacher of cancer biology and medicine. *PLoS Med* 2005;2:e349.
- [9] Moolgavkar S, Venzon DJ. Two-event models for carcinogenesis: incidence curves for childhood and adult tumors. *Math Biosci* 1979;47:55–77.
- [10] Greaves M. Darwinian medicine: a case for cancer. *Nat Rev Cancer* 2007;7:213–21.
- [11] Laconi E, Doratiotto S, Vineis P. The microenvironments of multistage carcinogenesis. *Semin Cancer Biol* 2008;18:322–9.
- [12] Thakkinian A, McElduff P, D'Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. *Stat Med* 2005;24:1291–306.
- [13] Higgins JPT, Green S, editors. *Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.* <<http://www.cochrane-handbook.org>>.
- [14] Chung TT, Pan MS, Kuo CL, Wong RH, Lin CW, Chen MK, et al. Impact of RECK gene polymorphisms and environmental factors on oral cancer susceptibility and clinicopathologic characteristics in Taiwan. *Carcinogenesis* 2011;32:1063–8.
- [15] Chu YH, Tzeng SL, Lin CW, Chien MH, Chen MK, Yang SF. Impacts of microRNA gene polymorphisms on the susceptibility of environmental factors leading to carcinogenesis in oral cancer. *PLoS One* 2012;7:e39777.
- [16] Yapjakis C, Serefoglou Z, Vylliotis A, Nkenke E, Derka S, Vassiliou S, et al. Association of polymorphisms in Tumor Necrosis Factor Alpha and Beta genes with increased risk for oral cancer. *Anticancer Res* 2009;29:2379–86.
- [17] Lin CW, Hsieh YS, Hsin CH, Su CW, Lin CH, Wei LH, et al. Effects of NFKB1 and NFKBIA gene polymorphisms on susceptibility to environmental factors and the clinicopathologic development of oral cancer. *PLoS One* 2012;7:e35078.
- [18] Bau DT, Tsai CW, Lin CC, Tsai RY, Tsai MH. Association of alpha B-crystallin genotypes with oral cancer susceptibility, survival, and recurrence in Taiwan. *PLoS One* 2011;6:e16374.
- [19] Mahjabeen I, Baig RM, Masood N, Sabir M, Malik FA, Kayani MA. OGG1 gene sequence variation in head and neck cancer patients in Pakistan. *Asian Pac J Cancer Prev* 2011;12:2779–83.
- [20] Pradhan S, Nagashri MN, Gopinath KS, Kumar A. Expression profiling of CYP1B1 in oral squamous cell carcinoma: counter intuitive down regulation in tumors. *PLoS One* 2011;6:e27914.
- [21] Cordero K, Espinoza I, Caceres D, Roco A, Miranda C, Squicciarini V, et al. Oral cancer susceptibility associated with the CYP1A1 and GSTM1 genotypes in Chilean individuals. *Oncol Lett* 2010;1:549–53.
- [22] Cha IH, Park JY, Chung WY, Choi MA, Kim HJ, Park KK. Polymorphisms of CYP1A1 and GSTM1 genes and susceptibility to oral cancer. *Yonsei Med J* 2007;48:233–9.
- [23] Wei S, Liu Z, Zhao H, Niu J, Wang LE, El-Naggar AK, et al. A single nucleotide polymorphism in the alcohol dehydrogenase 7 gene (alanine to glycine substitution at amino acid 92) is associated with the risk of squamous cell carcinoma of the head and neck. *Cancer* 2010;15(116):2984–92.
- [24] Huang YJ, Niu J, Wei S, Yin M, Liu Z, Wang LE, et al. A novel functional DEC1 promoter polymorphism – 249T>C reduces risk of squamous cell carcinoma of the head and neck. *Carcinogenesis* 2010;31:2082–90.
- [25] Chen K, Hu Z, Wang LE, Sturgis EM, El-Naggar AK, Zhang W, et al. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. *Carcinogenesis* 2007;28:2008–12.
- [26] Yu H, Huang YJ, Liu Z, Wang LE, Li G, Sturgis EM, et al. Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck. *Mol Carcinog* 2011;50:697–706.
- [27] Galli P, Cadoni G, Volante M, De Feo E, Amore R, Giorgio A, et al. A case-control study on the combined effects of p53 and p73 polymorphisms on head and neck cancer risk in an Italian population. *BMC Cancer* 2009;9:137.
- [28] Amtha R, Ching CS, Zain R, Razak IA, Basuki B, Roeslan BO, et al. GSTM1, GSTT1 and CYP1A1 polymorphisms and risk of oral cancer: a case-control study in Jakarta, Indonesia. *Asian Pac J Cancer Prev* 2009;10(1):21–6.
- [29] Lingen MW, Pinto A, Mendes RA, Franchini R, Czerninski R, Tilakaratne WM, et al. Genetics/epigenetics of oral premalignancy: current status and future research. *Oral Dis* 2011;17:7–22.
- [30] Blas E, Kurup AS. Equity, social determinants and public health programmes. 2010 WHO. WHO Library Cataloguing in Publication Data. <[http://whqlibdoc.who.int/publications/2010/9789241563970\\_eng.pdf](http://whqlibdoc.who.int/publications/2010/9789241563970_eng.pdf)>.
- [31] Brunotto M, Malberti A, Zárate A, Barra JL, Calderón O, Piñas E, et al. Early alterations of phenotype and genotype in rat Submandibular Gland oncogenesis. *Acta Odontol* 2006;19:13–21.
- [32] Brunotto M, Zarate AM, Barra JL, Malberti A. Graph models for phenotype and genotype association between oral mucosa and submandibular gland tumorigenesis in rat. *J Oral Pathol Med* 2009;38:463–9.
- [33] Li T, Kon N, Jiang L, et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. *Cell* 2012;149:1269–83.
- [34] Liu G, Parant JM, Lang G, et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. *Nat Genet* 2004;36:63–8.
- [35] Whibley C, Pharoah PD, Hollstein M. P53 polymorphisms: cancer implications. *Nat Rev Cancer* 2009;9:95–107.
- [36] Bergamaschi D, Samuels Y, Sullivan A, et al. IASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. *Nat Genet* 2006;38:1133–41.
- [37] Dumont P, Leu JI, Della Pietra III AC, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. *Nat Genet* 2003;33:357–65.
- [38] Sarkar J, Dominguez E, Li G, Kusewitt DF, Johnson DG. Modeling gene-environment interactions in oral cavity and esophageal cancers demonstrates a role for the p53 R72P polymorphism in modulating susceptibility. *Mol Carcinog* 2013. <http://dx.doi.org/10.1002/mc.22019>.
- [39] He XF, Su J, Zhang Y, et al. Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. *Breast Cancer Res Treat* 2011;130:517–29.
- [40] Jiang DK, Yao L, Wang WZ, et al. TP53 Arg72Pro polymorphism is associated with esophageal cancer risk: a metaanalysis. *World J Gastroenterol* 2011;17:1227–33.
- [41] MacFarlane LA, Murphy PR. MicroRNA: biogenesis, function and role in cancer. *Curr Genomics* 2010;11:537–61.
- [42] Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. *J Clin Oncol* 2010;28:1721–6.
- [43] Hausler SF, Keller A, Chandran PA, Ziegler K, Zipp K, Heuer S, et al. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. *Br J Cancer* 2010;103:693–700.
- [44] Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. *Urol Oncol* 2010;28:655–61.
- [45] Michael A, Bajracharya SD, Yuen PS, Zhou H, Star RA, Illei GG, et al. Exosomes from human saliva as a source of microRNA biomarkers. *Oral Dis* 2010;16:34–8.
- [46] Xiao W, Bao Z-X, Zhang C-Y, Zhang X-Y, Shi L-J, et al. Upregulation of miR-31\* is negatively associated with recurrent/newly formed oral. *Leukoplakia. PLoS One* 2012;7:e38648.
- [47] Xu Q, Ma P, Hu C, Chen L, Xue L, et al. Overexpression of the DEC1 protein induces senescence in vitro and is related to better survival in esophageal squamous cell carcinoma. *PLoS One* 2012;7:e41862.
- [48] Piva MR, DE Souza LB, Martins-Filho PR, Nonaka CF, De Santana Santos T, De Souza Andrade ES, et al. Role of inflammation in oral carcinogenesis (Part II): CD8, FOXP3, TNF- $\alpha$ , TGF- $\beta$  and NF- $\kappa$ B expression. *Oncol Lett* 2013;5:1909–14.
- [49] Hayden MS, Ghosh S. Signaling to NF-kappa B. *Genes Dev* 2004;18:2195–224.
- [50] Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. *Science* 2001;291:1284–9.
- [51] Wang M, Chu H, Zhang Z, Wei Q. Molecular epidemiologies of DNA repair gene polymorphisms and head and neck cancer. *J Biomed Res* 2013;27:179–92.
- [52] Galbiatti AL, Padovani-Junior JA, Maniglia JV, Rodrigues CD, Pavarino EC, Goloni-Bertollo EM. Head and neck cancer: causes, prevention and treatment. *Braz J Otorhinolaryngol* 2013;79:239–47.
- [53] Shahdoust M, Hajizadeh E, Mozdarani H, Chehrei A. Finding genes discriminating smokers from non-smokers by applying a growing self-organizing clustering method to large airway epithelium cell microarray data. *Asian Pac J Cancer Prev* 2013;14:111–6.
- [54] Boyle J, Gumus Z, Kacker A, et al. Transcriptome effects of cigarette smoke on the human oral mucosal. *Cancer Prev Res* 2010;3:264–78.
- [55] Pickett G, Seagrave J, Boggs S, et al. Effects of 10 cigarette smoke condensates on primary human airway epithelium cells by comparative gene and cytokine expression studies. *Toxicol Sci* 2010;114:79–89.
- [56] Wei Y, Zhou T, Lin H, Sun M, Wang D, Li H, et al. Significant associations between GSTM1/GSTT1 polymorphisms and nasopharyngeal cancer risk. *Tumour Biol* 2013;34:887–94.
- [57] Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. *Mayo Clin Proc* 2008;83:489–501.
- [58] Tramaceri I, Negri E, Bagnardi V, Garavello W, Rota M, Scotti L, et al. A meta-analysis of alcohol drinking and oral and pharyngeal cancers. Part 1: Overall results and dose-risk relation. *Oral Oncol* 2010;46:497–503.
- [59] Boffetta P, Winn DM, Ioannidis JP, Thomas DC, Little J, Smith GD, et al. Recommendations and proposed guidelines for assessing the cumulative evidence on joint effects of genes and environments on cancer occurrence in humans. *Int J Epidemiol* 2012;41:686–704.
- [60] Huang Z, Cheng Y, Chiu PM, Cheung FM, Nicholls JM, Kwong DL, et al. Tumor suppressor Alpha B-crystallin (CRYAB) associates with the cadherin/catenin adherens junction and impairs NPC progression-associated properties. *Oncogene* 2012;31:3709–20.

- [61] Su CH, Liu LC, Hsieh YH, Wang HC, Tsai CW, Chang WS, et al. Association of Alpha B-Crystallin (CRYAB) genotypes with breast cancer susceptibility in Taiwan. *Cancer Genomics Proteomics* 2011;8:251–4.
- [62] Huang YJ, Niu J, Liu Z, Wang LE, Sturgis EM, Wei Q. The functional IGFBP7 promoter-418G>A polymorphism and risk of head and neck cancer. *Mutat Res* 2010;702:32–9.
- [63] Bektas-Kayhan K, Ünür M, Yaylim-Eraltan I, Ergen A, Hafiz G, Karadeniz A, et al. Role of L-MYC polymorphism in oral squamous cell carcinoma in Turkey. *Anticancer Res* 2009;29:2519–24.
- [64] Ruiz MT, Balachi JF, Fernandes RA, Galbiatti AL, Maniglia JV, Pavarino-Bertelli EC, et al. Analysis of the TAX1BP1 gene in head and neck cancer patients. *Braz J Otorhinolaryngol* 2010;76:193–8.
- [65] Galbiatti AL, Ruiz MT, Raposo LS, Maniglia JV, Pavarino-Bertelli EC, Goloni-Bertollo EM. The association between CBS 844ins68 polymorphism and head and neck squamous cell carcinoma risk – a case-control analysis. *Arch Med Sci* 2010;6:772–9.